1021 CRISPRtx
BioCentury & Getty Images

Product Development

CRISPR’s data hint allogeneic CAR Ts may have the efficacy and safety issues of autologous therapies 

Oct 22, 2020 | 1:48 AM GMT

CRISPR Therapeutics’ first allogeneic CAR T therapy readout supports the idea that the therapeutic class can yield efficacy on par with autologous CAR Ts, without causing graft-versus-host disease.

But a patient death raises the possibility allogeneic CAR Ts won’t escape the safety issues of

Read the full 713 word article

How to gain access

Continue reading with a
two-week free trial.